| 查看: 924 | 回复: 6 | |||||||||
| 当前只显示满足指定条件的回帖，点击这里查看本话题的所有回帖 | |||||||||
[交流]
【2014-10-31】Pulsus出版集团当代医学论坛 & 征稿（通知）
|
|||||||||
Call for Papers Current Oncology (www.current-oncology.com) Current Oncology is a peer-reviewed, Canadian based and internationally respected journal, indexed by Science Citation Index (SCI) with an Impact Factor (IF) of 1.473 (2013 Journal Citation Reports, Science Edition). Published bi-monthly, plus special supplemental issues, Current Oncology represents a multidisciplinary medium encompassing health care workers in the field of cancer therapy to report upon and to review progress in the management of this disease. The journal publishes a range of article types that encompass all aspects of cancer medicine: Original articles, Review articles, Commentaries, Practice guidelines, Letters to the Editor Perspectives, Short communications and Case reports. Manuscripts must be solely the work of the author(s) stated, must not have been previously published elsewhere, and must not be under consideration by another journal. Articles published in the journal contain information that is relevant directly to clinical oncology practice, and have clear potential for application to the current or future practice of cancer medicine. Current Oncology aims to facilitate the communication from the laboratory to the bedside; contributing to cancer prevention, treatment, early detection, diagnosis, survivorship and rehabilitation. All papers should be written to be clearly understandable to the journal’s readers in a wide range of specialties. Submissions in the area of basic research are not accepted by the journal. In 2012, the journal had over 250 submissions and an article acceptance rate of 57%. Articles submitted to the journal undergo our rigorous peer review process and must be accepted prior to publication. For further information about our peer review policy, please visit https://www.current-oncology.com ... issions#PeerReview. Benefits of Publishing with Current Oncology include: • Articles are freely and permanently accessible online immediately upon publication 相关信息访问中文网站 “朋博学者网”通知 https://www.medicinepub.com/inde ... tid=3&id=22 [ Last edited by Paulwolf on 2014-11-19 at 05:50 ] |
回复此楼» 猜你喜欢
售一区SCI文章T0P，我:8O.551.O54,科目全,可十急
已经有3人回复
-
售SCI一区文章，我:8.O.551.O.5.4,科目全,可伽急
已经有3人回复
-
售SCI一区T0P文章，我:8.O55.1.O.54,科目全,可十急
已经有3人回复
-
售SCI一区T0P文章，我:8O.55.1.O.54,科目全,可伽急
已经有4人回复
-
售SCI一区T0P文章，我:8O.55.1.O.5.4,科目齐全,可+急
已经有3人回复
-
售SCI一区文章，我:8O5.5.1.O5.4,科目全,可伽急
已经有3人回复
-
售SCI一区T0P文章，我:8.O.55.1.O.5.4,科目全,可+急
已经有3人回复
-
售SCI-T0P文章，我:8O.5.5.1.O.54,科目齐全,可+急
已经有3人回复
-
售SCI一区T0P文章，我:8.O.55.1.O.5.4,科目全,可+急
已经有3人回复
-
售一区SCI文章T0P，我:8O.551.O54,科目全,可十急
已经有3人回复
7楼2014-10-20 15:22:51
简单回复
yuguiyan3楼
2014-10-19 21:27
回复
xmh880523(金币+1): 谢谢参与
， [ 发自小木虫客户端 ]
大内总管5楼
2014-10-19 21:33
回复
xmh880523(金币+1): 谢谢参与
